| Name | Title | Contact Details |
|---|---|---|
Anna Asberg |
SVP IT and global CIO | Profile |
Allison Sands |
Vice President Corporate Security and | Profile |
Marc Berson |
Senior Vice President and Chief Information Officer | Profile |
Bill Merritt |
Principal IT Security Architect, Security and Privacy | Profile |
Varun Goel |
IT Security and Risk Associate Director | Profile |
EYEVANCE Pharmaceuticals` mission is to develop and commercialize INNOVATIVE and IMPACTFUL ophthalmic products to enable optimal vision and better quality of life for all patients
MIND 24-7 is fundamentally changing the landscape of accessible behavioral health by offering walk-in urgent mental health and substance abuse services such as Psych Express Care, Psych Crisis Care, and Psych Progressions. MIND 24-7 fills the gap for those seeking help by being available right when they need it – 24 hours a day, 365 days a year. Using innovations in value-based care models to improve and expand access to care, MIND 24-7 not only enhances quality patient care, but reduces pressure on the system, reducing costly emergency room visits, in-patient treatment, and readmissions for crisis care.
At Advanced Orthopedics of Oklahoma, our specialty-trained orthopedic doctors and staff deliver the expert, compassionate care needed to heal, recover, and advance throughout Oklahoma in Tulsa, Claremore, Bixby, McAlester.
Pierre Fabre Laboratories is a Saint-Bruno, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.